Allen & Hanburys Ltd

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Patient Information Leaflet last updated on the eMC: 16/09/2011
PIL Seretide 50, 125, 250 Evohaler

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 16/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 27/09/2010 and displayed until 16/09/2011
Reasons for adding or updating:
  • Change to storage instructions
Updated on 07/12/2009 and displayed until 27/09/2010
Reasons for adding or updating:
  • Change to drug interactions
Updated on 03/06/2008 and displayed until 07/12/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change due to user-testing of patient information
Updated on 27/10/2005 and displayed until 03/06/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to how to administer the medicine
Updated on 08/02/2005 and displayed until 27/10/2005
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 21/12/2004 and displayed until 08/02/2005
Reasons for adding or updating:
  • Change to date of revision
  • Change to information about the device
  • Change to packaging
Updated on 11/03/2004 and displayed until 21/12/2004
Reasons for adding or updating:
  • Change to side-effects
Updated on 28/06/2002 and displayed until 11/03/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 13/11/2000 and displayed until 28/06/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   fluticasone propionate
   salmeterol xinafoate